|Seasoned Healthcare Executive Albert P. Parker Appointed Chief Operating Officer of OncoCyte|
“I welcome Al to
Prior to joining the Company, Mr. Parker served as the Managing Shareholder of
“OncoCyte’s focus on creating innovation in liquid biopsies, combined with its lead product DetermaVu, provides for unique strategic and operational growth opportunities and I am excited to join the team,” commented Mr. Parker.
DetermaVu™ is OncoCyte’s confirmatory, non-invasive, liquid biopsy test intended to facilitate clinical decision making in lung cancer diagnosis. DetermaVu™ is being developed as an intermediate step to confirm the absence of cancer between imaging modalities (LDCTs) detecting suspicious lung nodules and downstream invasive procedures that determine if the nodules are malignant.
DetermaVu™ is a trademark of
OncoCyte Forward Looking Statements
Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) are forward-looking statements. These statements include those pertaining to the implementation and results of research, development, clinical trials and studies, commercialization plans, future financial and/or operating results, and future opportunities for